Flumatinib
- Generic Name
- Flumatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H29F3N8O
- CAS Number
- 895519-90-1
- Unique Ingredient Identifier
- R4009Y24AI
- Background
Flumatinib has been used in trials studying the treatment of Myelogenous Leukemia, Chronic.
- Indication
用于治疗费城染色体阳性的慢性髓性白血病（Ph+CML）慢性期成人患者。
- Associated Conditions
- -
- Associated Therapies
- -
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-04-25
- Target Recruit Count
- 20
- Registration Number
- NCT05433532
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 2400
- Registration Number
- NCT05367765
- Locations
- 🇨🇳
Institute of Hematology and Oncology, Harbin The First Hospital, Harbin, Heilongjiang, China
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- wang, jianxiang
- Target Recruit Count
- 238
- Registration Number
- NCT05071482
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
- Conditions
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Shenzhen Second People's Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT04933526
- Locations
- 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 200
- Registration Number
- NCT04681820
- Locations
- 🇨🇳
Weiming Li, Wuhan, Hubei, China
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Shenzhen Second People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04677439
- Locations
- 🇨🇳
The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Zhongda Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT04375683
- Locations
- 🇨🇳
Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing, Jiangsu, China
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT01503502
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳The First Rffiurted Hospital of Soochow University, Suzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.